Amgen, Inc. is seeing an “increase in interest” from payers, pharmacy benefit managers and providers in the US biosimilar immunology/inflammation space, based on trends from previous launches, as it gears up to launch rivals to Humira (adalimumab) and Stelara (ustekinumab) in 2023 and beyond.
“I do think that interest in biosimilars will increase, and I think that biosimilar penetration of parent molecule or originator molecule will accelerate with new entrants,” commented global commercial operations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?